Form 4: CEO Sells PAHC Shares Under Pre-Arranged 10b5-1 Plan

Phibro Animal Health CEO Jack Bendheim and BFI Co., LLC sold 21,120 shares of Class A Common Stock through a pre-arranged trading plan.

Summary

• Jack Bendheim, President and CEO, Director, and 10% Owner of Phibro Animal Health Corp (PAHC), along with BFI Co., LLC, reported sales of Class A Common Stock.
• A total of 21,120 shares were sold across multiple transactions between February 24, 2026, and February 26, 2026.
• The sales were executed pursuant to a Rule 10b5-1 trading plan adopted by BFI Co., LLC on May 30, 2025.
• On February 24, 2026, 5,889 shares were sold at a weighted average price of $51.2679 (ranging from $50.755 to $51.75).
• Also on February 24, 2026, an additional 1,151 shares were sold at a weighted average price of $51.8799 (ranging from $51.80 to $52.065).
• On February 25, 2026, 7,040 shares were sold at a weighted average price of $51.7104 (ranging from $51.275 to $52.27).
• On February 26, 2026, 6,329 shares were sold at a weighted average price of $53.669 (ranging from $53.21 to $54.10).
• Also on February 26, 2026, 711 shares were sold at a weighted average price of $54.2826 (ranging from $54.27 to $54.355).
• Following these transactions, BFI Co., LLC beneficially owns 1,480 shares indirectly, and Jack Bendheim directly owns 16,840 shares of Class A Common Stock.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event because the sales were pre-scheduled under a 10b5-1 plan, which typically indicates personal financial planning rather than a reaction to new company-specific information.

Positives

• The sales were conducted under a Rule 10b5-1 trading plan, indicating pre-scheduled divestment rather than a reaction to new, non-public information, which enhances transparency.

Negatives

• The transactions represent a reduction in the beneficial ownership stake of a key insider, Jack Bendheim, and BFI Co., LLC, which could be perceived as a slight negative by some investors.

Management Comments

• The reported sales were effected pursuant to a Rule 10b5-1 trading plan adopted by BFI Co., LLC on May 30, 2025.
• Jack Bendheim, a reporting person, director and officer of the Issuer, exercises voting and dispositive power over BFI and may be deemed to have shared voting and investment power over the securities held by BFI. Mr. Bendheim disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.

Industry Context

StockSavvy.ai notes that insider sales, especially by high-ranking executives and significant owners, are closely watched by the market. While sales under a 10b5-1 plan are pre-scheduled and often for personal financial planning, a reduction in insider ownership can sometimes be interpreted as a lack of confidence, though this is mitigated by the pre-planned nature of these transactions.

Stakeholder Impact

• Shareholders will observe a reduction in the beneficial ownership of a key executive and significant shareholder, which may lead to questions regarding insider confidence, though the 10b5-1 plan mitigates immediate concerns.

Key Dates

Recommendation

The sales by a key insider, while significant in volume, were conducted under a pre-arranged 10b5-1 trading plan. This suggests personal financial planning rather than a reaction to new material information about Phibro Animal Health Corp. Therefore, it does not provide a strong signal for a change in investment thesis, warranting a 'hold' recommendation.

Keywords

Phibro Animal Health, PAHC, Jack Bendheim, Insider Sale, Form 4, 10b5-1 Plan, Stock Transaction, CEO, Director, 10% Owner